Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8266MR)

This product GTTS-WQ8266MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8266MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4690MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ9619MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ12710MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ2255MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALX-0171
GTTS-WQ14000MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ15520MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA UCB-7858
GTTS-WQ7276MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ2614MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 557
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW